Kyowa Kirin Co., Ltd. (KYKOY) Gagner

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 5,161 full-time employees. The firm operates in Pharmaceuticals business segment. The firm engages in the research, development, manufacture, sale, and import & export of prescription pharmaceuticals. The firm has drug discovery technologies in antibody therapeutics and hematopoietic stem cell gene therapy. Its development pipeline includes AMG531 for aplastic anemia untreated with immunosuppressive therapy, KHK4083/AMG 451 for moderate to severe atopic dermatitis, KHK4083/AMG 451 for moderate to severe asthma, and KK2845 for acute myeloid leukemia and others. In addition, through its subsidiaries, the Company develops, manufactures, markets, and contracts out biosimilar pharmaceuticals, and engages in wholesale and retail sales and insurance agency business. The firm operates in Japan and overseas.